In a report released today, Hartaj Singh from Oppenheimer maintained a Buy rating on Moderna Inc (MRNA). The company’s shares opened today at $22.47.
According to TipRanks.com, Singh is a 4-star analyst with an average return of 3.3% and a 48.0% success rate. Singh covers the Healthcare sector, focusing on stocks such as Strongbridge Biopharma Plc, Catabasis Pharmaceuticals, and Actinium Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Moderna Inc with a $25.13 average price target, an 11.8% upside from current levels. In a report issued on March 6, Needham also maintained a Buy rating on the stock with a $28 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $24.40 and a one-year low of $13.03. Currently, Moderna Inc has an average volume of 1.1M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics.
